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012.06.0Abstract Background: The aim was to determine the efﬁcacy of heart-type fatty acid-binding pro-
tein (H-FABP) compared with routinely myoglobin (MYO), creatine kinase-MB (CK-MB) and car-
diac troponin-I (cTn-I) in the early diagnosis of acute myocardial infarction (AMI) in patients
presenting with acute chest pain.
Methods and results: The patients were classiﬁed as AMI (n= 22), unstable angina (UA, n= 20)
and non-cardiac chest pain (NCCP, n= 15) within 3 h and 6 h of acute chest pain according to the
American College/European Society of Cardiology; and normal healthy subjects (controls, n= 10).
Blood H-FABP levels were measured by ELISA and compared with cTn-I, CK-MB and MYO in
all subjects. The diagnostic sensitivity, speciﬁcity and receiver operating characteristic (ROC) curve
were evaluated. Serum H-FABP, MYO, CK-MB and cTn-I were signiﬁcantly higher in AMI more
than the UA, NCCP (non-AMI) and control groups within 6 h. However, Serum H-FABP, MYO
and CK-MB were signiﬁcantly elevated within 0–3 h and extend more within 3–6 h in AMI versus
non-AMI. The cutoff value of H-FABP in AMI was 21.85 ng/ml within 3 h, and has diagnostic sen-
sitivity (81.8%) equal to that of CK-MB and cTn-I but superior to that of MYO (72.7%). However,
H-FABP has higher speciﬁcity (88.2%) equal to that of MYO but superior to that of CK-MB and
cTn-I. This trend extends to within 6 h as well. Moreover, ROC curve areas for H-FABP were sig-
niﬁcantly higher (p< 0.05) than other biomarkers <6 h after the onset of chest pain.
Conclusion: H-FABP can be used as a sensitive biomarker for myocardial injury in early stage.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.El Amin St., Sharaf Square,
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041. Introduction
Major causes of acute chest pain include cardiac, gastro-esoph-
ageal, musculoskeletal and pulmonary conditions.1 Forty per-
cent (40%) of patients presenting with acute chest pain could
be spared the risks and costs of unnecessary hospital admission
and more invasive cardiac testing by simply adding test to the
diagnostic protocol to rule out heart attack.2,3 Identiﬁcation
and management or excluding of patients with acute chest pain
due to acute myocardial infarction (AMI) is a common andg by Elsevier B.V. All rights reserved.
180 I. Elmadbouh et al.difﬁcult challenge for emergency physicians.4,5 Thus, early
AMI diagnosis relies crucially on the cardiac biochemical
markers in these cases.2
Old biochemical markers were used as AMI indicators such
as serum aspartate transaminase (AST) and lactic dehydroge-
nase-1 (LDH-1).6 Myoglobin (MYO), creatine kinase-MB
(CK-MB), troponin T and I (cTn-T, cTn-I) are nowadays
widely used in diagnosing patients with acute chest pain for
the detection of myocardial tissue damage and also manage
high-risk patients.7–9 However, they do not possess high diag-
nostic sensitivity or speciﬁcity for AMI in early stage, espe-
cially within 3 h after onset of persistent angina pectoris.9,10
Recently, another cardiac biomarkers such as glycogen phos-
phorylase BB (GP-BB) and carbonic anhydrase III (CA-III)
were assessed,7,11 but until now, the ideal marker is not
present.
Recently, Heart-type fatty acid binding protein (H-FABP)
is about 10-fold lower in skeletal muscle than that in heart
muscle, and the amounts in the kidney, liver, small intestine,
brain, lactating mammary glands and the placenta are even
lower.9 H-FABP can be transported from severely damaged
cardiomyocytes to the blood more rapidly than other markers
such as MYO, cTn-I and CK-MB.12 MYO is more sensitive in
the early phase of AMI, but its speciﬁcity is not satisfying. H-
FABP as a marker of myocardial ischemia even in the absence
of frank necrosis, and may be a useful tool as prognostic value
of elevated H-FABP for monitoring of a recurrent infarction.4
H-FABP may be useful in low and intermediate risk patients
with suspected acute coronary syndrome with negative tropo-
nins.12 The magnitude of the increase in plasma H-FABP has
also demonstrated a good correlation with the size of the
infarction.6 In the clinical studies, serum H-FABP level is also
elevated under hypertrophic and dilated cardiomyopathy,
heart failure, hypertension, aortic valve regurgitation and pul-
monary embolism.6
H-FABP might have potential as an early cardiac bio-
marker, although the clinical impact of this better diagnostic
performance remains unclear.13 Therefore, the aim of this
study was to determine the efﬁcacy of H-FABP compared with
routinely MYO, cTn-I and CK-MB in the early diagnosis of
AMI in patients presenting with acute chest pain in emergency
room. Also, H-FABP can differentiate between cardiac and
non-cardiac acute chest pain.
2. Subjects and methods
2.1. Study subjects
This study was carried out on 67 subjects: 57 patients and 10
healthy subjects (controls). The patients were selected from
Intensive Care Unit, Cardiology Department, Menouﬁya Uni-
versity Hospital between November 2009 and May 2010. The
protocol of this study was approved by the local ethics commit-
tee, Faculty ofMedicine, Menouﬁya University; and written in-
formed consent was obtained from every subject participating in
this study.
Patients presenting with acute chest pain more than 30 min
and less than 6 h suspected of AMI, unstable angina and non-
cardiac chest pain were enrolled consecutively in the study.
These patients were also randomly classiﬁed according the
time of chest pain onset into two groups (0–3 and 3–6 h). Fullhistory taking including patients’ symptoms and past medical
history such as diabetes mellitus (DM), hypertension (HTN)
and previous ischemic event; and general clinical examination,
ECG and laboratory investigations were documented at
admission using a pre-deﬁned protocol.
Diagnostic criteria: The standard diagnosis was made after
critical review of all the clinical pictures and relevant informa-
tion by a senior cardiologist. AMI was deﬁned according to
the European Society of Cardiology/American College of Car-
diology Committee Criteria.5,14 AMI was deﬁned as detection
of initial or 6 h cTn-IP 0.1 ng/ml together with evidence of
myocardial ischemia with at least one of the following: (i)
symptoms of ischemia; (ii) ECG changes indicative of new
ischemia (new ST-T changes or new left bundle branch block
[LBBB]); (iii) development of pathological Q waves in the
ECG; (iv) imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality. Diagnostic out-
comes were ﬁrst categorized into the following groups: (i)
ST-elevation myocardial infarction (STEMI); (ii) non-ST-ele-
vation myocardial infarction (NSTEMI); (iii) unstable angina
(UA); and (iv) non-cardiac chest pain (NCCP). The ﬁrst two
groups were later integrated into AMI group, and the last
two into non-myocardial infarction (non-AMI) group. Con-
trols were selected on the basis of healthy condition without
cardiovascular diseases, lung and kidney diseases, with normal
blood pressure and electrocardiogram, normal serum lipids
and normal blood glucose.
N.B: In this study, NCCP patients included chest wall dis-
eases and trauma, gall bladder stones, gastritis, peptic ulcer,
pulmonary embolism, pleuritis, psychic, bronchial asthma, mi-
tral valve prolapse and reﬂux oseophagitis.
Exclusion criteria: Patients with one of the following criteria
are excluded: arrival to the hospital over 6 h after the onset of
chest pain; patients who underwent percutaneous transluminal
coronary angioplasty or coronary artery bypass grafting with-
in 30 days; patients who had prior AMI within 30 days; having
chronic muscle disease; receiving direct current (DC) shock; re-
nal insufﬁciency or any renal disease impairing renal clearance;
and recent surgery (cardiac and non-cardiac).
2.2. Laboratory analysis
Only one venous blood sample (10 ml) was withdrawn by ster-
ile venous puncture and clean dry syringes from the cubital
vein of every investigated subject at the time of admission to
the hospital within 6 h after the onset of symptoms. Blood ser-
um was separated from the clot and liquated under complete
aseptic condition. The serum obtained was kept frozen at
20 C till the analysis of serum AST, ALT, total cholesterol,
triglyceride, creatinine, cTn-I, CK-MB, MYO and H-FABP.
Myoglobin (MYO) was determined by enzyme linked immu-
nosorbent assay (ELISA, DRG International Inc., USA). This
assay system utilizes a unique monoclonal antibody directed
against a distinct antigenic determinant on the myoglobin mol-
ecule such as mouse monoclonal anti-myoglobin antibody.
Also, the assay for measuring cTn-I (Enzyme-Linked
Fluorescent Assay, ELFA, BioMerieux Inc., USA) and CK-
MB (enzyme linked immunosorbent assay, ELISA, Oxis Inter-
national Inc., USA) in routine clinical practice at our recruiting
hospital was upgraded partway through the study. However,
cTn-I and CK-MB value used in routine clinical practice for
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positive throughout the study period.
The H-FABP was determined by enzyme linked immuno-
sorbent assay (ELISA, Biocheck Inc., USA). The assay system
utilizes an afﬁnity puriﬁed goat anti-H-FABP antibody. H-
FABP kit was applied to qualitatively determine the H-FABP
levels in blood samples with a cut-off level at >19 ng/ml.
MYO, cTn-I and CK-MB were determined with cut-off levels
of 85 ng/ml, 0.11 lg/l, and 5.2 ng/ml respectively.
Any results that were equal or more the cut-off levels were
deﬁned as positive results. Conversely, those being less than
the cut-off levels were deﬁned as negative results. Regarding
the combinations, positive results were deﬁned as positive of
any component markers, while negative results were deﬁned
as negative of all the component markers.
2.3. Statistical analysis
Results were statistically analyzed by IBM personal computer
and statistical package SPSS version 11. Mean ± standard
deviation (SD), percentage (%), Student’s t test and Mann–
Whitney test (non-parametric test) were used in the assessment
of AMI and non-AMI groups. Chi-square (v2) test, sensitivity,
speciﬁcity, positive and negative predictive values, diagnostic
accuracy and ROC (receiver operating characteristic) curve
were used to assess the diagnostic validity of H-FABP, CK-
MB, MYO and cTn-I. Multiple groups’ comparison was made
by the non-parametric Kruskall and Wallace test and paired
comparisons were made by Wilcoxon rank test. Results are gi-
ven as mean ± SD, cut-off values according to sample timesTable 1 Clinical parameters of all subjects within 6 h from the ons
AMI (n= 22) UA (n= 20) NCC
Age (years) 58.0 ± 10.65 56.10 ± 9.30 37.1
Sex n (%)
Male 18 (81.8%) 16 (80.0%) 7 (4
Female 4 (18.2%) 4 (20.0%) 8 (5
Smoking n (%)
Positive 14 (63.6%) 13 (65.0%) 4 (2
Negative 8 (36.4%) 7 (35.0%) 11 (
Hypertension n (%)
Positive 7 (31.8%) 13 (65.0%) 1 (6
Negative 15 (68.2%) 7 (35.0%) 14 (
DM n (%)
Positive 10 (45.5 %) 7 (35.0%) 5 (3
Negative 12 (54.5%) 13 (65.0%) 10 (
Family history n (%)
Positive 6 (27.3%) 7 (35.0%) 2 (1
Negative 16 (72.7%) 13 (65.0%) 13 (
P1: \AMI versus Control, \\UA versus Control, \\\NCCP versus control
P2: \AMI versus UA, \\AMI versus NCCP, \\\UA versus NCCP.(95% conﬁdence interval, CI). P values < 0.05 were consid-
ered statistically signiﬁcant.3. Results
Sixty-seven subjects were enrolled in the study and divided into
four groups: Group 1: Acute myocardial infarction (AMI) pa-
tients (n= 22, 18 males and 4 females). Their ages were ranged
between 35 and 76 years with mean 58.0 ± 10.65 years. Group
2: Unstable angina (UA) patients (n= 20, 16 males and 4 fe-
males). Their ages were ranged between 27 and 74 years with
mean 56.10 ± 9.30 years. Group 3: Non-cardiac chest pain
(NCCP) patients (n= 15, 8 males and 7 females). Their ages
were ranged between 18 and 71 years with mean
37.13 ± 14.51 years. Group 4: healthy subjects as controls
(n= 10, 6 males and 4 females). Their ages were ranged be-
tween 24 and 74 years with mean 52.10 ± 12.96 years. Statisti-
cally, there were signiﬁcant in age of patients between groups
measured by Kruskal Wallis test (20.73, p< 0.001), but there
were not signiﬁcant in gender measured by Chi-square (v2) test
(6.79, p> 0.05).
Incidence of smoking, history of DM and hypertension
were signiﬁcantly higher in AMI than the control groups. Inci-
dence of smoking and hypertension was signiﬁcantly higher in
UA than the control groups. All parameters in AMI group
were signiﬁcantly higher than those in the non-AMI (UA
and NCCP) and control groups within 6 h (see Table 1)
Serum H-FABP, MYO and CK-MB were signiﬁcantly in-
creased in 0–3 h with more increased in 3–6 h after chest painet of chest pain.
P (n= 15) Control (n= 10) P1 value P2 value
3 ± 14.51 43.10 ± 18.13 <0.05\ >0.05\
<0.05\\ <0.001\\
>0.5\\\ <0.001\\\
6.7%) 6 (60.0%) >0.5\ >0.05\
3.3%) 4 (40.0%) >0.5\\ <0.05\\
>0.5\\\ <0.05\\\
6.7%) 2 (20.0%) <0.05\ >0.05\
73.3%) 8 (80.0%) <0.05\\ <0.05\\
>0.05\\\ <0.05\\\
.7%) 0 >0.05\ <0.05\
93.3%) 10 (100%) <0.01\\ >0.05\\
>0.05\\\ <0.001\\\
3.3%) 0 <0.05\ >0.05\
66.7%) 10 (100%) >0.05\\ >0.05\\
>0.05\\\ >0.05\\\
3.3%) 2(20.0%) >0.05\ >0.05\
86.7%) 8 (80.0%) >0.05\\ >0.05\\
>0.05\\\ >0.05\\\
.
Figure 1 Comparison of plasma concentration of H-FABP (A), Myoglobin (B), CK-MB (C) and cTn-I (D) among the groups at 0–3 h
and 3–6 h from onset chest pain. Results were expressed as mean ± SD.
Table 2 Diagnostic validity of four cardiac biomarkers between AMI and non-AMI patients within 3 h and 6 h from the onset of
chest pain.
H-FABP (ng/ml) Myoglobin (ng/ml) CK-MB (ng/ml) cTn-I (lg/l)
Level of cutoﬀ point
0–3 21.85 72.35 2.49 0.085
3–6 31.45 96.9 5.7 0.13
Area under curve ROC (95% CI)
0–3 0.896 (0.733–1.059) 0.818 (0.627–1.009) 0.738 (0.538–0.938) 0.765 (0.572–0.957)
3–6 0.992 (0.971–1.01) 0.975 (0.927–1.02) 0.997 (0.987–1.0) 0.975 (0.926–1.02)
Sensitivity (%)
0–3 81.8 72.7 81.8 81.8
3–6 100 100 100 100
Speciﬁcity (%)
0–3 88.2 88.2 41.2 76.5
3–6 88.9 88.9 94.9 77.8
PPV (%)
0–3 81.8 80 47.4 69.2
3–6 84.6 84.6 91.7 73.3
NPV (%)
0–3 88.2 83.3 77.8 86.7
3–6 100 100 100 100
Accuracy (%)
0–3 85.7 82.1 57.1 78.6
3–6 93.1 93.1 96.6 86.2
182 I. Elmadbouh et al.of AMI. Whereas, serum cTn-I was non-signiﬁcant increased
in Fig. 1.
The diagnostic sensitivity and speciﬁcity of cut-off values
and area under the ROC curves for H-FABP, MYO, cTn-Iand CK-MB are shown in Table 2. H-FABP possessed higher
sensitivity than that of cTn-I and CK-MB at all time points
after the onset of symptoms. The sensitivity of H-FABP within
3 h was 81.8% and reached 100% within 3–6 h. H-FABP has
Figure 2 ROC curves of concentration of H-FABP, cTn-I, CK-
MB and Myoglobin (MYO) in patients with suspected AMI versus
non-AMI at 0–3 h (A) and 3–6 h (B) from the onset of chest pain.
Cardiac biomarker in patients with acute chest pain 183higher sensitivity than MYO within 3 h. The speciﬁcity data
for non-AMI were signiﬁcantly higher among the H-FABP
and MYO at all time points after the onset of symptoms.
The overall speciﬁcity within 3–6 h was 88.9% for H-FABP
and equal to MYO but, 77.8% for cTn-I, 94.9% for CK-
MB. Also, the areas under the ROC curves of H-FABP and
MYO in the AMI group were signiﬁcantly higher (p< 0.05)
than other biomarkers in the non-AMI group at 3 h and 6 h
in Table 2. The data from ROC analysis are summarized in
Fig. 2; ROC curves were constructed by plotting the sensitivity
for the conﬁrmed AMI group (n= 22) on the Y-axis and 1-
speciﬁcity for the non-AMI group (n= 35) on the X-axis with-
in 3 h and 6 h after the onset of chest pain.
4. Discussion
AMI is the main cause of mortality and disability in the mod-
ern world. Early and correct diagnosis is of great importance
to enable immediate and intensiﬁed treatment which conse-
quently reduces mortality .9 If treatment of AMI is done within
1 h (the golden hour) effectively, mortality can be reduced
from 9% to 3%, if delay of 3–4 h, mortality could be ﬁve times
higher.4 However, the golden moment for optimal outcome of
coronary revascularization is within 4 h after the onset of
occlusive coronary thrombosis so early diagnosis is important
for cardiac etiology in patients presenting with acute chest
pain.8 Unfortunately, at least one-ﬁfth of AMI is clinically
unrecognized because of the absence of chest discomfort or
atypical ECG changes.15,16 Early diagnosis of AMI has great
clinical signiﬁcance, because the duration of symptoms has a
strong impact on the hospital management strategy.2 Our goal
will require altering the current methods of cardiac biomarkers
for identifying such patients.
The heart is a poor fatty acid synthesizer, and contributes
only 0.1% of total body fatty-acid synthesis, but accounts
for 10% of the total body turnover of fatty acids. H-FABPmay constitute the intracellular equivalent of albumin for the
intracellular transport of the insoluble fatty acids within the
myocytes.6 The protective role for H-FABP, as scavengers of
free radicals17 and against detergent-like effects of locally high
concentrations of long-chain fatty acids18, particularly during
cardiac ischemia.12
Our study showed that H-FABP has greater diagnostic va-
lue in patients with suspected AMI than does cTn-I, CK-MB
or MYO within 3 h following onset of acute chest pain rather
than at a later 6 h. These results were similar to other pub-
lished previously.4,9,10,19 Consequently, H-FABP concentra-
tions have a greater predictive capacity for cardiac events
than cardiac troponin within 3 h of the onset of chest pain.
Conﬂicting results about cardiac markers may be explained
by the duration of AMI at the time of sampling or other fac-
tors in AMI studies.20 H-FABP appears in plasma 1–3 h with
peak at 6 h after cardiac damage, and may be the earliest avail-
able plasma marker of acute myocardial injury and returns to
normal values in 12–24 h.15 However, CK-MB begins to in-
crease between 3 and 5 h after the onset of infarction and peak-
ing at 16–20 h.11 CK-MB is not perfectly speciﬁc to cardiac
injury as it increases during massive musculo-skeletal injury.19
Moreover, MYO lacks speciﬁcity because it is released from
skeletal muscles and cannot be distinguished from that re-
leased from the heart.21
The superior performance of H-FABP may be attributed to
the following two factors: (i) smaller molecular weight: H-
FABP is a small cytoplasmic protein, which has a very low
molecular weight of 15 kDa, while the molecular weights of
MYO, cTn-I and CK-MB are 18, 22.5 and 80 kDa respec-
tively13; (ii) steeper tissue-to-plasma gradient: The myocardial
content of H-FABP (0.52 mg/g wet wt) is 4.5-fold lower than
that of MYO (2.35 mg/g wet wt), yet the basic plasma level
of H-FABP (2.8 lg/l) is 10-fold lower than the later (30 lg/
l).15,21 So H-FABP tissue-to-plasma gradient is at least two-
fold steeper than that of MYO. This characteristic, along with
the higher permeability of the endothelial barrier for small pro-
teins, enable H-FABP to exhibit an early and signiﬁcant re-
lease after myocardial injury with or without necrosis and
make it more easily being detected. The presence of myocardial
ischemia resulting in chest pain might result from coronary
spasm in the presence of atheroma but in the absence of plaque
erosion/rupture and thrombus formation. Such patients might
be expected to have no detectable troponins and yet have an
elevated H-FABP and, importantly, an increased risk of future
major cardiovascular event.
Our data demonstrate that the cut off value of H-FABP for
the diagnosis of AMI from cases of acute chest pain within 3 h
of onset was 21.85 ng/ml and H-FABP has sensitivity equal to
that of CK-MB and superior to that of MYO. This trend ex-
tends to the 6 h of myocardial injury as well. This result is con-
ﬁrmed by other studies.22–25 However, the speciﬁcity of MYO
and H-FABP was the same percentage value but more superior
than cTn-I and CK-MB which was similar to other
study.19,26,27
The current study showed that acute chest pain within 0–
3 h, the areas under the ROC curve for H-FABP and MYO
in the AMI group were highly signiﬁcant than in the non-
AMI group which was similar to that reported in multicenter
EUROCARDI trials27 and other study.19
This study showed that the cut off value of H-FABP for the
diagnosis of AMI from cases of acute chest pain within 3–6 h
184 I. Elmadbouh et al.of onset was 31.45 ng/ml. At this cut off value, the sensitivity
was 100% and equal to that of the MYO, However, the spec-
iﬁcity of H-FABP was 88.9% which is equal to MYO and
higher than cTn-I but, lower than that of CK-MB. These re-
sults were similar to that reported in other publications.9,19
Conclusion: H-FABP can detect early myocardial injury
(infarction) and can exclude other acute non-cardiac chest pain
causes within 3 h. H-FABP can be useful in the early diagnosis
of acute chest pain in comparison with other traditional bio-
markers CK-MB, cTn-I and MYO. Combining H-FABP and
MYO provides the best performance for early AMI diagnosis.
Emergency departments are under increasing pressure to
process patients in less time. Therefore, a test that stratiﬁes
the risk of patients with chest pain more rapidly would be valu-
able, facilitating earlier discharge. It is recommended to use H-
FABP bedside test. It can easily be performed by drawing four
drops of capillary whole blood from the patient’s ﬁnger and
applying them onto the test-strip within 15 min for cTn-I,
CK-MB, MYO and H-FABP.2,4,11
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